COVID-19 on Disease Activity in Radiologically Isolated Syndrome Cohort
NCT05387395 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 217
Last updated 2022-08-01
Summary
The Radiologically Isolated Syndrome (RIS) is defined as incidental Magnetic Resonance Imaging (MRI) abnormalities fulfil the criteria for dissemination in space, suggestive of multiple sclerosis. Nowadays, mandatory vaccination in patients with multiple sclerosis (MS) is widely recommended. Regarding COVID19, the absence of specific warnings led to the proposal of vaccination in patients with inflammatory diseases of the central nervous system. We aimed to evaluate if COVID19 vaccination or infection increased the risk of clinical conversion to multiple sclerosis or evidence of disease activity (EDA) in a cohort of RIS subjects.
Conditions
Interventions
- OTHER
-
NO intervention
no intervention
Sponsors & Collaborators
-
Centre Hospitalier Universitaire de Nice
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-05-31
- Primary Completion
- 2022-07-01
- Completion
- 2022-07-01
Countries
- France
Study Locations
More Related Trials
-
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
NCT00239655 ·Status: TERMINATED ·Phase: PHASE2
-
Immunisation Status and Safety of Vaccines in Italian MS Patients
NCT04300868 ·Status: UNKNOWN
-
Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis
NCT04834401 ·Status: COMPLETED
-
Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS
NCT04838015 ·Status: UNKNOWN
-
A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, Canada
NCT02367222 ·Status: COMPLETED
-
Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study
NCT05197699 ·Status: TERMINATED
-
Impact of the Modifications of Environmental Exposures and Health Care Access During COVID-19 Lockdown on Multiple Sclerosis
NCT05033782 ·Status: COMPLETED
-
A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab
NCT06460324 ·Status: COMPLETED
-
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
NCT00001248 ·Status: RECRUITING
-
Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
NCT04869358 ·Status: COMPLETED ·Phase: PHASE4
-
Protection Against Severe Coronavirus Disease 2019 in Patients With Multiple Sclerosis Stratified According to Disease Modifying Treatment
NCT05834335 ·Status: COMPLETED
-
Study of Empathy in MS
NCT05332951 ·Status: COMPLETED
-
Improved Detection of Multiple Sclerosis Plaques in Inversion Recovery by Optimization of Sequence Parameters
NCT03108573 ·Status: COMPLETED
-
Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid.
NCT06395662 ·Status: ACTIVE_NOT_RECRUITING
-
Vancomycin Study in Multiple Sclerosis (MS)
NCT05539729 ·Status: RECRUITING ·Phase: PHASE1
-
Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
NCT01071512 ·Status: COMPLETED ·Phase: NA
-
Epidemiological Characteristics of COVID-19 in Patients With MS or NMO
NCT04355611 ·Status: COMPLETED
-
Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis
NCT00202410 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study on Cognitive Disorders of Multiple Sclerosis
NCT01074619 ·Status: COMPLETED ·Phase: PHASE3
-
Epstein Barr Virus Infection in Patients With Radiologically Isolated Syndrome
NCT05815108 ·Status: COMPLETED
-
Vaccine Exposure in Patients With MS
NCT03191669 ·Status: COMPLETED
-
COVID-19 Vaccine Response in Treated MS Patients
NCT05060354 ·Status: COMPLETED
-
MS Relapses During COVID-19 Pandemic
NCT04858763 ·Status: COMPLETED
-
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
NCT00097331 ·Status: COMPLETED ·Phase: PHASE2
-
A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
NCT04847596 ·Status: COMPLETED